KALA BIO Inc (KALA)

[stockguard]

Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals (KALA) yesterday and set a price target of $49.00. The company’s shares closed last Thursday at $7.08.

According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 14.7% and a 57.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kala Pharmaceuticals with a $26.25 average price target.

Based on Kala Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.22 million and GAAP net loss of $27.95 million. In comparison, last year the company earned revenue of $1.45 million and had a GAAP net loss of $23.18 million.

Kala Pharmaceuticals (NASDAQ:KALA) has commercially launched EYSUVIS 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
The company says that it is progressing its development of pre-clinical stage new chemical entities targeted to address front and back of the eye diseases.
Expects cash, cash equivalents and short-term investments of ~$153.5M as of December 31, 2020, including net proceeds from ATM offering during Q4, to fund its operations into at least 4Q22.